For some women, times of reproductive transition represent times of high risk for the onset or exacerbation of depressive symptoms. In order to maintain emotional stability, the female brain must adapt to fluctuations in hormones that affect neurotransmitter functioning. Difficulty with this adaptation, along with stresses related to social role transitions, may confer heightened vulnerability to depression. In this review, we summarize data regarding the course, expression and risks of depression and related symptoms during puberty and menarche, the luteal phase of the menstrual cycle, the perinatal period and perimenopause. We note treatment strategies that have been found to be effective for depressive symptoms during specific phases of the female reproductive cycle. †
is somewhat higher in boys; after puberty, the prevalence markedly increases in girls relative to boys [6] . Among adolescent girls, pubertal stage predicts the emergence of depression better than age [7] . The incidence and persistence of depres sive symptoms increase across pubertal stages in girls, but not in boys [8] .
In addition to posited hormonal influences, factors that increase vulnerability to depression in pubertal girls include: body dissatisfaction, sex ual abuse, cognitive styles and coping s trategies, and early puberty onset.
Body dissatisfaction
Bodily changes that result from puberty in girls may move them away from a culturally ascribed 'thin ideal'. As a result, pubertal girls tend to express more body dissatisfaction than boys, with pubertal boys more often pleased with the changes occurring in their bodies. Body dissatis faction is a significant influence on the e mergence of depression among adolescent girls [9] .
Sexual abuse
Sexual abuse is more prevalent in girls than boys. It is a major risk factor for the emergence of depression in adolescent girls [10] .
Cognitive styles & coping strategies
On average, boys and girls tend to develop dif ferent styles of thinking regarding stressful life events. More girls than boys are inclined to ruminate on problems, to believe that negative events are their fault and to believe that nega tive events will always happen to them. More boys than girls take an active problemsolving approach to stress. The cognitive styles that pre dominate in girls correlate with the likelihood of developing depressive disorders [11] .
Sex and gender influence the prevalence, expres sion, course and response to treatment of depres sive disorders. Sex influences vulnerability to depression partly through hormonal and genetic effects on the developing fetal brain [1] . Posited gender influences on depression include cultural gender roles, differential stressors and differing cognitive styles [2] .
For some women, times of reproductive transi tion pose a high risk for the onset or exacerba tion of depressive or dysphoric symptoms. Sex hormones modulate neurotransmitter systems that regulate mood [3] . The female brain relies on mechanisms to adapt to hormonal flux, such as rapid upregulation and downregulation of neurotransmitter receptors [4] . Insufficient adap tive mechanisms could render some women vul nerable to dysphoria during times of hormonal change. Since times of hormonal change are often times of social role change, the unique social stressors associated with reproductive transitions can further increase vulnerability to depression.
In this review, we highlight clinically rele vant data regarding depressive and dysphoric symptoms related to women's reproductive cycle events: puberty and menarche, the menstrual cycle, the perinatal period and perimenopause. These data can inform interventions that are tai lored to each reproductive stage [5] . Since this review is intended as a literature update, data are included and summarized based on clini cal relevance, with no specific methodologic i nclusion criteria.
Among girls, early onset of puberty and men arche is associated with increased rates of depres sive symptoms [12, 13] . Mediating factors may include increased peer pressure, early sexual activity and increased body dissatisfaction in girls who mature early [14] . In addition, parental conflict and other stressors in the family envi ronment may heighten the risk (independently or interactively) for both earlyonset puberty and depression [15] .
Assessment & treatment
A comprehensive assessment of adolescent girls whose depressive symptoms began during peri menarche includes asking about contributory factors, such as sexual abuse, body dissatisfac tion, early sexual activity, peer pressure and family conflicts. Ascertaining a girl's usual approach to stressful situations may help to identify her cognitive style and coping strate gies. The presence of these contributory factors can inform treatment. For example, psycho therapy could be focused on developing effec tive problem solving skills, navigating family conflict, resisting peer pressure, recovering from sexual trauma and/or improving selfesteem and body image. Targeted psychotherapy is a first line treatment for depression in adolescent girls, owing to data suggesting an increased risk of suicide in a dolescents who take a ntidepressant m edications [5] .
Premenstrual dysphoric disorders

Types of premenstrual dysphoric disorders
Many women experience physical, psychologi cal and/or behavioral changes related to their menstrual cycles. In approximately 1-8% of women of reproductive age, these changes meet the diagnostic criteria for premenstrual dys phoric disorder (PMDD) [16] [17] [18] . By definition, women with PMDD experience at least five of 11 specific symptoms, beginning during the last week of the postovulatory phase of the men strual cycle, remitting at, or shortly after, the onset of menses, and causing functional impair ment. At least one symptom must be mood related (e.g., depression, anxiety, irritability or mood lability) [19] . Among these mood symp toms, irritability is the most common [20, 21] . Other symptoms can include reduced energy, difficulty concentrating, changes in sleep and/ or appetite, feeling overwhelmed, joint or muscle pain, breast tenderness or swelling and abdominal bloating. Approximately 12-18% of women of reproductive age experience premen strual dysphoric symptoms that cause distress and/or impairment, but have fewer than five discrete symptoms [22, 23] .
A related problem is premenstrual exacerba tion (PME) of depression during the late luteal phase of the menstrual cycle. Women experienc ing PME have symptoms that meet diagnostic criteria for recurrent major depression, but with a clinically significant increase in severity and likelihood of symptom recurrence during the postovulatory part of the menstrual cycle [24] .
Although it is not understood why some women are vulnerable to premenstrual dys phoric symptoms, indirect evidence supports the hypothesis that some women's nervous sys tems are sensitive to cyclic changes in gonadal hormones [25] . Estrogen and progesterone influ ence the functioning of neurotransmitters, such as serotonin and gaminobutyric acid (GABA), that play a key role in mood states. A number of studies have found that women with PMDD have serotonergic and GABAergic abnormali ties in the symptomatic luteal phase of their cycles, but not in the asymptomatic follicular phase [26] . Genetic variations in estrogen recep tors that may underlie differential neurotrans mitter and n europeptide sensitivity are being explored [27] .
Assessment of premenstrual dysphoric symptoms
Charting daily variations in symptoms for at least two menstrual cycles helps elucidate whether symptoms are linked to the menstrual cycle, and, if so, their pattern and severity. Scheduling two evaluation sessions, one pre menstrual and one after menses onset, allows the clinician to compare symptoms and mental status examination at different cycle phases. For women already taking antidepressant medica tion, checking pre and postmenstrual serum levels can help to determine whether pharma cokinetics differ substantially at different cycle phases [28] . In some women, hormonal influ ences on pharmacokinetics result in cyclically subtherapeutic medication levels that can be confused with PME.
Treatment & intervention
Since women may experience a wide variety of premenstrual symptoms, and exhibit marked individual differences in treatment responsive ness, a multifaceted treatment approach is often indicated. Interventions with some demon strated efficacy are summarized in this section. For many women, a key component of treat ment is a serotonergic antidepressant [29] . Among these, fluoxetine, paroxetine and sertra line are approved by the US FDA for the treat ment of PMDD. Other antidepressants with serotonergic activity, including citalopram, clomipramine, escitalopram, f luvoxamine, nefazodone and venlafaxine, have been demon strated to be superior to placebo for treating premenstrual dysphoric symptoms [30] [31] [32] [33] . By contrast, antidepressants with little to no sero tonergic activity, such as buproprion, mapropti line and desipramine, have been found to be no more effective than placebo in treating PMDD [34] [35] [36] .
For premenstrual symptoms, antidepressants can be administered in a variety of dosing pat terns, as summarized in Table 1 . Choice of dos ing regimen depends on patient preferences and tolerability of side effects.
Continuous dosing involves administering the antidepressant daily, at a consistent dose. Women with comorbid mood or anxiety disor ders, those who have irregular menstrual cycles or difficulty keeping track of their cycles, and patients subject to adverse effects from abrupt medication discontinuation may benefit from continuous dosing.
Lutealphase dosing involves initiating treat ment at the time of ovulation (approximately day 14 of a 28day cycle) and discontinuing 1-2 days after menses begins. A meta analysis of 29 serotonergic antidepressant treatment studies demonstrated that intermittent dosing was significantly more effective than placebo for premenstrual symptom reduction, but was somewhat less effective than continuous dos ing [37] . A lutealphase dosing strategy is suit able for women with regular menstrual cycles who are able to adhere to the on/off timing, have no symptoms during the follicular phase and are concerned regarding medication side effects.
Symptomonset dosing involves beginning medication as soon as premenstrual symptoms are noticed and stopping medication within 3 days of menses onset [38] . A study comparing symptomonset and lutealphase dosing of esci talopram for PMDD found significant improve ment using either dosing strategy, although women with severe PMDD were less likely to improve with symptomonset dosing [39] .
Lutealphase boosting involves increasing the antidepressant dose during the luteal phase and decreasing to a lower dose at onset of menses. Limited data suggest that this dosing strategy is effective for women with PME [40] .
Approximately 40% of women with PMDD do not respond to serotonergic medications [41] . Nonresponders and partial responders require a more comprehensive approach, using one or more of the interventions described below.
Anxiolytic medication
Anxiolytic medications are not FDAapproved for the treatment of PMDD. Studies of the efficacy of benzodiazepines for PMDD symp toms show mixed results [42] [43] [44] . Buspirone, a non benzodiazepine anxiolytic agent, may be effective for alleviating PMDD symptoms, but data are limited [45, 46] . In clinical practice, ben zodiazepines may be used during the evaluation phase to alleviate anxiety while charting symp toms, for temporary relief while initiating lon gerterm treatment, or as needed for o ccasional b reakthrough symptoms.
Hormonal intervention
Oral contraceptive pills have variable effects on premenstrual mood, with most women expe riencing no change, and more women experi encing worsening than improvement [47] . One exception is drospirenone/ethinyl estradiol, administered as 24 days of active pills followed by a 4day drugfree interval, the only oral contraceptive agent FDAapproved for treat ing PMDD [48] . Pilot data suggests that this Table 1 . Dosing strategies for premenstrual psychiatric symptoms.
Dosing strategy Description
Continuous dosing Medication is administered everyday throughout the menstrual cycle Luteal-phase dosing Medication is started at ovulation, on approximately day 14 of a 28-day period, and stopped 1-2 days after menstrual bleeding begins Symptom-onset dosing Medication is started as soon as premenstrual symptoms are noticed, and stopped 1-2 days after menstrual bleeding begins Luteal-phase boosting A higher dose is started at ovulation, on approximately day 14 of a 28-day period, and lowered 1-2 days after menstrual bleeding begins agent may also be effective as an adjunct to antidepressants for premenstrual exacerbation of depression [49] . Gonadotropinreleasing hor mone (GnRH) agonists are also effective [50] . These medications cause a 'chemical menopause' and are generally used only for temporary relief in severe cases, although ongoing research is investigating ways to 'add back' estrogen and progesterone in order to improve safety without causing symptom recurrence [51] . Hysterectomy with oophorectomy is effective, and can be con sidered in women with GnRHresponsive symp toms who have an additional indication for the surgery [52, 53] .
Herbal therapy
In a randomized, doubleblind, placebocon trolled trial, vitex agnus castus (chasteberry) extract significantly decreased anger, irritabil ity, headache and breast fullness compared with placebo [54] . When compared with fluoxetine in a randomized, singleblind trial, chasteberry was equally effective overall, but fluoxetine was more effective for emotional symptoms while chasteberry was more effective for physical symptoms [55] .
Nonpharmacologic interventions
Nonpharmacologic approaches can help to ameliorate premenstrual dysphoric symptoms, with or without adjunctive medication. These include cognitivebehavioral therapy [56] , aerobic exercise [57] and calcium supplementation [58] .
Promising pilot data suggest that further study of phototherapy and biofeedback is warranted [59] .
Perinatal depression Description & prevalence of perinatal mood changes
Approximately 9.4-12.7% of pregnant women develop a major depressive episode during preg nancy [60] . Untreated depressive symptoms dur ing pregnancy are associated with an increased risk of preterm birth [61] and enduring changes in infant temperament and subsequent stress response in offspring [62] . Three distinct but overlapping types of post partum mood disturbances are 'blues', depres sion and psychoses. Postpartum 'blues' is a nor mal mood change experienced by approximately 50% of women within the first few weeks after delivery, characterized by pronounced emotional reactivity but not a sustained, predominant depressed mood [63] . Postpartum major depres sion is experienced by up to 21.9% of peri natal women within the first year after giving birth [60] . Postpartum depression may reduce breastfeeding [64] , impair parenting capability in conjunction with other risk factors [65] , and adversely affect children's cognitive, emotional and behavioral development [66, 67] . Postpartum psychotic symptoms arise in approximately one in 1000 women giving birth, but in up to 35% of women with bipolar diatheses [68] . Postpartum psychotic symptoms are most often part of a mood episode, whether manic, depressive or mixed [69] . Onset is usually within the first 3 weeks after delivery, often beginning within the first 3 days [70] . Compared with nonpost partum psychotic mood episodes, there is more disorientation and mood lability in postpartum episodes [71] [72] [73] . Difficulty with neuronal adap tation to abrupt hormonal change is posited to contribute to vulnerability to each of these postpartum mood states [74] . Other posited contributory factors to postpartum depression include heightened postpartum inflammatory responses and hypothalamic-pituitary-adrenal axis dysregulation [75, 76] . Psychosocial risk fac tors may also be influential, such as difficulty adjusting to unrealistically high personal and social e xpectations regarding motherhood [77] .
Treatment of perinatal depression
When considering pharmacotherapy for peri natal psychiatric symptoms, the risks of untreated symptoms must be weighed against the risks of medication. Relapse rates are high for women with major depression who discontinue medica tion while pregnant [78] . Risks of medication can be reduced by choosing agents that have been relatively well studied in human pregnancy and have not been associated with major neonatal or pregnancy complications. Emerging data are also suggesting dosing strategies during pregnancy that can minimize risks, such as using pharmaco kinetic measures to titrate dosing, or using par tial dose tapers near the end of pregnancy to reduce the risk of neonatal withdrawal [79] .
Interpersonal psychotherapy has been found to be effective for treating and preventing peri natal depression, particularly in women having dif ficulty navigating perinatal role transitions [80] . If maternal psychiatric symptoms have impaired the mother-infant relationship, mother-infant psychotherapy may be helpful [81] .
Perimenopause & depression
Impact of perimenopause on depression
The transition to menopause is a time of height ened risk of depressive symptoms. It is esti mated that there is at least a twofold increase Depression & related disorders during the female reproductive cycle -Review in newonset depressive symptoms and major depressive episodes during perimenopause [82] . The risk of developing depressive symptoms is especially high when levels of sex hormones fluctuate most [83] . There are some data suggest ing that women with histories of PMDD and/or postpartum depressive symptoms may be more vulnerable to perimenopausal depression [84, 85] .
Factors that may contribute to depressive symptoms in perimenopausal women include:
• Stress: perimenopausal women have greater physiologic reactivity to stress than premeno pausal women [86] . Unanticipated stress, uncon trollable stress and stressors that adversely affect selfesteem are especially likely to contribute to perimenopausal depression [87] . Frequent midlife stressors include career problems, deaths and serious illnesses of significant oth ers, as well as parenting, marital tensions and role changes [88] ;
• Hot flashes: women who experience hot flashes are significantly more likely to develop depres sive symptoms. While some have posited a 'domino effect' (i.e., physical discomfort and/or resultant sleep deprivation leading directly to depression), most studies have found that hot flashes and depressive symptoms are correlated, but without one causing the other [89] ;
• Other health problems: women who experi ence chronic medical problems, such as migraines, diabetes and fibromyalgia, may be more vulnerable to perimenopausal depression, especially if they experience role l imitations owing to health problems [90, 91] ;
• Personal and cultural attitudes: attitudes regarding menopause, and the role of older women in a given culture, may influence the likelihood that a woman will become depressed in the transition to menopause [92] .
Assessment of perimenopausal women for depression
Untreated depression can increase medical morbidity after menopause, including risks from cardiovascular disease [93] , diabetes [94] and osteoporosis [95] . The high prevalence and risks of untreated symptoms suggest that universal screening for depression is warranted among perimenopausal women in primary care settings [96] . This can be accomplished with validated selfreport questionnaires, such as the nineitem Patient Health Questionnaire (PHQ9) [97] . The PHQ9 facilitates the diag nosis of major and minor depression, rates symptom severity and can be used to track response to treatment. Once a woman has been diagnosed with peri menopausal depression, assessing for contribu tory factors and protective factors can help guide an effective treatment plan. Relevant factors to assess are shown in Table 2 .
Treatment & intervention
Effective treatment for perimenopausal depres sion is usually multifaceted, directed at reducing contributory factors and enhancing protective factors. Interventions can include: antidepressant medication, estrogen therapy, p sychotherapy, and exercise and physical activity.
Antidepressant medication
When choosing antidepressant medication for perimenopausal women, it is helpful to select agents that simultaneously treat other symptoms, such as hot flashes or pain, without compound ing comorbid medical problems or risking dan gerous drug-drug interactions. Antidepressants that have been demonstrated to reduce hot flashes in at least some studies include parox etine, fluoxetine, citalopram, venlafaxine and desvenlafaxine [98] . Serotoninnorepinephrine Strong social support network; employment; more formal education reuptake inhibitor antidepressants can reduce chronic pain, but the serotoninnorepinephrine reuptake inhibitor venlafaxine may cause hyper tension [99] . Antidepressants that cause sedation or postural hypotension could increase the risk of falls, in turn increasing fracture risk in women with osteoporosis. Selective serotonergic reup take inhibitor antidepressants may reduce bone density [100] , which can be monitored as needed for women at risk of osteoporosis.
Estrogen therapy
Estrogen has antidepressant properties in some women. Although study findings are not con sistent, available data suggest that women most likely to benefit from estrogen are:
• Women who are perimenopausal, not post menopausal [101] [102] [103] ;
• Women with minor depression, not major depression [104] ;
• Women with a partial response to antidepres sant medication, with estrogen used in order to a ugment response [104, 105] .
Caveats regarding the use of estrogen as an antidepressant are that its use for this purpose is not FDAapproved, that the risk:benefit ratio is unclear, and that there are insufficient data on optimal dosing and formulations of estrogen [5] .
Psychotherapy
Interpersonal psychotherapy is useful for peri menopausal women whose depression is influ enced by problems with role transitions, such as career changes, marital stress and parenting problems [106] . It can help women reexamine and shed constricting roles, adopt new roles and negotiate with others for support.
Cognitivebehavioral therapy is useful for peri menopausal women whose depression is influenced by difficulty managing midlife stress ors and/or by negative attitudes toward aging. It can help women learn to counter negative thoughts, solve problems and activate them selves when depressive symptoms lead them to feel unmotivated and isolated [107] .
Exercise & physical activity
Physical activity alleviates depressive symp toms, while also promoting general health after menopause [108] . However, physical activity declines after menopause in many women [109] . Clinicians can be effective in encouraging women to increase physical activity levels via the following interventions:
• Comprehensive assessment to determine whether there are medical limitations on intensity and type of exercise, and to allay unfounded anxieties regarding medical risks of exercise or vigorous physical activity [110] ; • Helping women define effective goals for exer cise. Research suggests that women whose goals are to increase wellbeing and reduce stress sustain physical activity more effectively than women whose goal is to lose weight [111] ; • Emphasizing the importance of making time for selfcare [112] ; • Focusing on how women can integrate more physical activity into their daily routines, emphasizing that several small increments of activity throughout the day are as effective as one sustained exercise session [110, 112] ; • Helping women identify physical activities they enjoy [112] .
Conclusion
Most women do not develop depressive symp toms during reproductive transitions. However, evidence is accumulating to support the hypo thesis that some women have a heightened vul nerability to emotional disturbance at times of rapid hormonal flux. Understanding the influence of these reproductive transitions and incorporating evidencebased treatment modi fications geared to each reproductive phase can promote optimal mental health in women.
Future perspective
Research is elucidating how genetic makeup, hormonal exposure and environmental stressors interact to shape sex and gender differences in psycho pathology. Studies are exploring the rea sons for sexual dimorphism in the brain, which begins during fetal development. Researchers are investigating the implications of this sexual dimorphism for normal behavior and psycho pathology, including how small inborn sex dif ferences are shaped and amplified by subsequent hormonal flux, life experiences and cultural gender roles. Normative data concerning sex differences, gender differences and the influence of repro ductive cycle events may facilitate the develop ment of more effective treatments for depres sion during perimenarche, the luteal phase of the menstrual cycle, pregnancy, the postpartum period and perimenopause. Pharmacokinetic and pharmaco genomic studies are shedding light on how pharmacotherapy could be modified to give optimal therapeutic results for individual women future science group Since heightened risk of depression is a predict able accompaniment of reproductive cycle events for some women, prevention of such risk is pos sible and essential. Research is underway to better identify girls and women at risk for reproductive linked depressive episode, and to understand how to protect women's brains at vulnerable times.
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Executive summary
Introduction
• Times of rapid hormonal flux confer a high risk of development or exacerbation of psychiatric symptoms for a subset of women.
• High-risk reproductive transitions include puberty and menarche, the luteal phase of the menstrual cycle, the perinatal period and perimenopause.
Premenstrual dysphoric disorders
• Approximately 1-8% of menstruating women experience premenstrual dysphoric disorder (PMDD).
• Some women experience a separate but related condition, premenstrual exacerbation (PME) of depression.
• PMDD can be treated with serotonergic antidepressant medication, administered as a continuous dose, luteal-phase dose or symptom-onset dose. • PME can be treated with serotonergic antidepressant medication, administered as a continuous dose or luteal-phase boosted dose.
• Additional interventions for PMDD include psychotherapy, aerobic exercise, calcium supplementation, drospirenone/ethinyl estradiol and vitex agnus castus.
Perinatal depression
• The perinatal period is a time of heightened risk for depression.
• This heightened risk may be due to a combination of factors, including failure of the CNS to adapt to abrupt hormonal change, hypothalamic-pituitary-adrenal axis dysregulation, heightened postpartum inflammatory response and psychosocial stressors. • Treatment considerations include weighing the risks of medication against the risks of untreated symptoms, and using prescribing practices that reduce the risks of medications for the woman, her fetus and/or her breastfed infant. • Interpersonal psychotherapy, cognitive-behavioral therapy and mother-infant therapy can be effective for specific types of symptoms and problems.
Perimenopause & depression
• Rates of depression increase during perimenopause, especially in women with histories of premenstrual and/or postpartum depression.
• The risk of developing perimenopausal depressive symptoms is influenced by midlife stress, general health problems, perimenopausal physical symptoms and cultural attitudes toward aging. • Antidepressant medication can be chosen to reduce other symptoms, such as pain and/or hot flashes, and with care not to increase other midlife health risks, such as fractures and hypertension. • Estrogen supplementation is not generally effective as monotherapy for major depression, but can alleviate symptoms of minor depressive symptoms in some women, and may be an effective adjunct when depressive symptoms respond partially to an antidepressant. • Psychotherapy and aerobic exercise can help to alleviate perimenopausal depressive symptoms.
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